C

Climb Bio Inc
D

CLYM

17.830
USD
1.44
(8.79%)
مغلق
حجم التداول
33,641
الربح لكل سهم
-1
العائد الربحي
-
P/E
-22
حجم السوق
1,024,088,427
المقالات
المزيد

العنوان: Climb Bio Inc

القطاع: الرعاية الصحية
الصناعة: Biotechnology
Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.